文献速递泌尿男性生殖肿瘤

达罗他胺联合ADT和多西他赛在mHSPC中的临床相关终点与生活质量:ARASENS III期试验分析

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.
PubMed 文献 · Eur J Cancer · 2026-06-12

ARASENS试验纳入1305例mHSPC患者,随机接受达罗他胺或安慰剂联合ADT和多西他赛。达罗他胺显著延长至mCRPC时间和至疼痛进展时间,疼痛干扰/严重程度及NFPSI-17评分恶化时间组间相似,长期治疗未累积TEAE。

要点

  • 达罗他胺三联显著延迟至mCRPC时间(HR 0.36)和至疼痛进展时间(HR 0.79)。
  • 疼痛干扰/严重程度及NFPSI-17评分恶化时间两组相似,HRQoL维持。
  • 长期治疗(中位随访>3.5年)未观察到累积性TEAE。

核心结论

  • 达罗他胺联合ADT和多西他赛在临床相关终点上显著优于ADT和多西他赛,疼痛控制相似、HRQoL维持且长期治疗无累积TEAE。

研究设计与样本

  • ARASENS为III期随机试验(NCT02799602),mHSPC患者随机接受达罗他胺600 mg口服每日两次或安慰剂,联合ADT和多西他赛。
  • 分析人群共1305例(达罗他胺651例,安慰剂654例),中位随访>3.5年。

主要发现

  • 达罗他胺显著延迟至mCRPC时间(HR 0.36 [95%CI 0.30-0.42])和至疼痛进展时间(HR 0.79 [95%CI 0.66-0.95])。
  • 至疼痛干扰/严重程度恶化和NFPSI-17评分恶化的时间两组相似。
  • 常见与雄激素受体通路抑制相关的TEAE发生率总体较低且组间相似。

临床怎么用

  • 达罗他胺联合ADT和多西他赛可作为mHSPC的标准治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metastatic hormone-sensitive prostate cancer (mHSPC) require long-term treatment to delay progression and improve survival, while minimizing adverse events or negative impact on symptoms (e.g. pain) and health-related quality of life (HRQoL). In ARASENS (NCT02799602), darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly improved overall survival (primary endpoint) versus placebo plus ADT and docetaxel. We report clinically relevant endpoints and HRQoL in ARASENS. METHODS: Patients with mHSPC were randomized to darolutamide 600 mg orally twice daily or placebo, with ADT and docetaxel. Outcomes of interest were times to metastatic castration-resistant prostate cancer (mCRPC), pain progression, worsening of Brief Pain Inventory-Short Form pain interference/severity, and worsening of National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Prostate Cancer Symptom Index 17-item questionnaire (NFPSI-17) scores. RESULTS: In 1305 patients analyzed (darolutamide 651, placebo 654), darolutamide significantly delayed time to mCRPC (hazard ratio 0.36 [95 % confidence interval 0.30-0.42]) and time to pain progression (0.79 [0.66-0.95]) versus placebo. Times to worsening of pain interference/severity and NFPSI-17 scores were similar between treatment groups. Incidences of treatment-emergent adverse events (TEAEs) commonly associated with androgen receptor pathway inhibition were generally low and similar between groups (median follow-up: > 3.5 years). CONCLUSION: Darolutamide plus ADT and docetaxel provided significant benefits in clinically relevant endpoints versus ADT and docetaxel, with similar control of pain, maintenance of HRQoL, and no cumulative TEAEs over long-term treatment. These data reinforce darolutamide triplet therapy as a standard-of-care treatment option in patients with mHSPC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Smith MR, Hussain M, et al. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. Eur J Cancer. 2026. PMID: 42378957. doi:10.1016/j.ejca.2026.116888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。